Product Description: Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[1][2][3].
Applications: Neuroscience-Neurodegeneration
Formula: C10H19Cl2N3S
Citations: J Affect Disord. 2024 Apr 22:356:586-596./J Stroke Cerebrovasc Dis. 2023 Apr 25;32(7):107142./J Stroke Cerebrovasc Dis. 2024 Oct 26:108101./PeerJ. 2023 Sep 11./Neurochem Int. 2021 Jan 22;104972./Prog Neurobiol. 2023 Oct 5:102536.
References: [1]Kvernmo, T., et al. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther, 2006. 28(8): p. 1065-78./[2]Takashi Okura, et al. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sci. 2007 Apr 3;80(17):1564-71./[3]Ginetta Collo, et al. Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling. Neural Plast. 2018; 2018: 4196961./[4]P M Carvey, et al. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm (Vienna). 1997;104(2-3):209-28./[5]Syed Suhail Andrabi, et al. Pramipexole prevents ischemic cell death via mitochondrial pathways in ischemic stroke. Dis Model Mech. 2019 Aug 1; 12(8): dmm033860.
CAS Number: 104632-25-9
Molecular Weight: 284.25
Compound Purity: 99.73
Research Area: Neurological Disease
Solubility: DMSO : 175 mg/mL (ultrasonic)/H2O : ≥ 50 mg/mL
Target: Dopamine Receptor
Deutsch
English
